Full Breakdown
Novo Nordisk’s Q1 2026 Results Highlight Wegovy Pill’s Strong Launch Amid Heightened Competition
5/6/2026, 10:30:47 PM
Q1 2026 Earnings and Pill Performance
Novo Nordisk posted Q1 revenue of 96.8 billion DKK ($15.2 bn), a 32 % constant-currency increase. Reported operating profit rose 65 % to 59.6 billion DKK, boosted by a $4.2 bn reversal of a 340B-program provision. Adjusted sales fell 4 % and adjusted profit declined 6 % to 32.86 billion DKK. The Wegovy oral pill generated 2.26 billion DKK ($355 m) in sales, with about 1.3 million prescriptions in the quarter and more than 2 million since its January launch.
Competitive Landscape and Pricing Policy
The launch occurs as Eli Lilly’s oral obesity drug Foundayo entered the U.S. market in April, challenging Novo’s first-mover advantage. U.S. “most-favoured-nation” (MFN) pricing rules, advocated by the Trump administration, could tie U.S. prices to lower-priced markets, adding further pricing pressure.
Performance Metrics
Wegovy’s 2.26 billion DKK sales exceeded analyst forecasts of 1.16 billion DKK. The product captured 65 % of all new U.S. obesity-drug prescriptions and drove prescription volumes above 200,000. Higher-dose formulations accounted for roughly 16 % of Wegovy orders.
Market Implications
The strong pill uptake narrowed the projected sales decline and lifted Novo’s share price by roughly 6-7 % in early trading. Volume growth offsets lower injectable prices, though analysts question the durability of this offset.
Company Statements
Novo said the Wegovy pill is “driving a strong start to 2026” and that competition with Lilly is “so far, so good.” The company added that MFN considerations are part of planning but not a limiting factor, and that the oral product is not cannibalising injectables.
Analyst Concerns
Critics point to the reliance on wholesale stocking and lower-dose usage, which may constrain long-term profitability. The 340B provision reversal inflated reported profit, while adjusted figures show a decline. Some investors question whether volume growth can fully offset U.S. price cuts and Foundayo’s entry.
Data Discrepancies
Adjusted sales decline is reported as 4 % in some releases and 10 % in others. Share-price moves range from a 2.3 % to a 9 % rise. Wegovy’s revenue share is cited as 4-5 % or “a modest part.” Higher-dose uptake data remain limited.
Verbatim Quotes
- “The numbers with the pill speak for themselves,” — Mike Doustdar, CEO, Novo Nordisk
- “We are ?considering MFN obviously as part of our planning, but it's not a limiting factor,” — Mike Doustdar, CEO, Novo Nordisk
- “It is no secret that the Wegovy pill is off to a record-breaking start in the U.S.,” — Mike Doustdar, CEO, Novo Nordisk
Outlook
Novo aims to obtain European regulatory approval for the Wegovy pill in the second half of 2026 and will monitor Foundayo’s market penetration and MFN pricing impacts while targeting double-digit prescription growth.
